相似文献
1
NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential.
Nat Rev Drug Discov. 2006 Sep;5(9):755-68. doi: 10.1038/nrd2038.
2
NO-independent, haem-dependent soluble guanylate cyclase stimulators.
Handb Exp Pharmacol. 2009(191):277-308. doi: 10.1007/978-3-540-68964-5_13.
3
Exploring the potential of NO-independent stimulators and activators of soluble guanylate cyclase for the medical treatment of erectile dysfunction.
Curr Pharm Des. 2010 May;16(14):1619-33. doi: 10.2174/138161210791164162.
4
Distinct molecular requirements for activation or stabilization of soluble guanylyl cyclase upon haem oxidation-induced degradation.
Br J Pharmacol. 2009 Jul;157(5):781-95. doi: 10.1111/j.1476-5381.2009.00263.x. Epub 2009 May 18.
5
Nitric oxide-independent stimulation of soluble guanylate cyclase with BAY 41-2272 in cardiovascular disease.
Cardiovasc Drug Rev. 2007 Spring;25(1):30-45. doi: 10.1111/j.1527-3466.2007.00003.x.
6
Molecular mechanisms underlying rat mesenteric artery vasorelaxation induced by the nitric oxide-independent soluble guanylyl cyclase stimulators BAY 41-2272 [5-cyclopropyl-2-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-4-ylamine] and YC-1 [3-(5'-hydroxymethyl-2'-furyl)-1-benzyl Indazole].
J Pharmacol Exp Ther. 2006 Apr;317(1):258-66. doi: 10.1124/jpet.105.095752. Epub 2005 Dec 13.
7
The chemistry and biology of soluble guanylate cyclase stimulators and activators.
Angew Chem Int Ed Engl. 2013 Sep 2;52(36):9442-62. doi: 10.1002/anie.201302588. Epub 2013 Aug 20.
8
NO-independent regulatory site of direct sGC stimulators like YC-1 and BAY 41-2272.
BMC Pharmacol. 2001;1:13. doi: 10.1186/1471-2210-1-13. Epub 2001 Dec 28.
9
NO- and haem-independent activation of soluble guanylyl cyclase: molecular basis and cardiovascular implications of a new pharmacological principle.
Br J Pharmacol. 2002 Jul;136(5):773-83. doi: 10.1038/sj.bjp.0704778.
10
Heme-dependent and independent soluble guanylate cyclase activators and vasodilation.
J Cardiovasc Pharmacol. 2010 Sep;56(3):229-33. doi: 10.1097/FJC.0b013e3181eb4e75.
引用本文的文献
1
Lipocalin-2 Restores Soluble Guanylyl Cyclase-Dependent Dilation of the Afferent Arteriole After Renal Transplantation or Ex Vivo Hypoxia/Reoxygenation in Mice.
Acta Physiol (Oxf). 2025 Aug;241(8):e70077. doi: 10.1111/apha.70077.
2
Analysis of research trends and development prospects of soluble guanylate cyclase stimulators/activators: using bibliometric methods.
Front Pharmacol. 2025 Jun 10;16:1501330. doi: 10.3389/fphar.2025.1501330. eCollection 2025.
3
Neuroprotective Effect of a Novel Soluble Guanylate Cyclase Activator Runcaciguat in Diabetic and Ischemic Retinopathy.
Diabetes. 2025 Jul 1;74(7):1220-1232. doi: 10.2337/db24-0739.
4
Molecular Mechanisms Underlying Heart Failure and Their Therapeutic Potential.
Cells. 2025 Feb 20;14(5):324. doi: 10.3390/cells14050324.
5
Nutritional L-Citrulline and Tetrahydrobiopterin in Peripheral Artery Disease: A Phase II Randomized Trial (CIPER Study).
JACC Adv. 2025 Mar;4(3):101590. doi: 10.1016/j.jacadv.2025.101590. Epub 2025 Feb 21.
6
Soluble guanylate cyclase stimulators and activators as potential antihypertensive drugs.
Hypertens Res. 2025 Apr;48(4):1458-1470. doi: 10.1038/s41440-025-02110-5. Epub 2025 Jan 20.
7
The α- and β-Subunits of Nitric Oxide-Sensitive Guanylyl Cyclase in Pericytes of Healthy Human Dental Pulp.
Int J Mol Sci. 2024 Dec 24;26(1):30. doi: 10.3390/ijms26010030.
8
The Influence of Cell Isolation and Culturing on Natriuretic Peptide Receptors in Aortic Vascular Smooth Muscle Cells.
Cells. 2025 Jan 4;14(1):51. doi: 10.3390/cells14010051.
9
Decoding signaling mechanisms: unraveling the targets of guanylate cyclase agonists in cardiovascular and digestive diseases.
Front Pharmacol. 2023 Dec 20;14:1272073. doi: 10.3389/fphar.2023.1272073. eCollection 2023.
10
Vericiguat protects against cardiac damage in a pig model of ischemia/reperfusion.
PLoS One. 2023 Dec 22;18(12):e0295566. doi: 10.1371/journal.pone.0295566. eCollection 2023.
本文引用的文献
1
Targeting the heme-oxidized nitric oxide receptor for selective vasodilatation of diseased blood vessels.
J Clin Invest. 2006 Sep;116(9):2552-61. doi: 10.1172/JCI28371.
2
NO-independent activation of soluble guanylate cyclase prevents disease progression in rats with 5/6 nephrectomy.
Br J Pharmacol. 2006 Jul;148(6):853-9. doi: 10.1038/sj.bjp.0706792. Epub 2006 Jun 12.
3
Functional characterization of two nucleotide-binding sites in soluble guanylate cyclase.
J Biol Chem. 2006 Aug 4;281(31):21763-21770. doi: 10.1074/jbc.M508983200. Epub 2006 Jun 5.
4
Protective effects of BAY 41-2272 (sGC stimulator) on hypertension, heart, and cardiomyocyte hypertrophy induced by chronic L-NAME treatment in rats.
J Cardiovasc Pharmacol. 2006 Mar;47(3):391-5.
5
Drug discovery technology Europe 2006 - IBC's Tenth Annual Conference and Exhibition.
IDrugs. 2006 Apr;9(4):256-60.
6
BAY 41-2272, a direct activator of soluble guanylate cyclase, reduces right ventricular hypertrophy and prevents pulmonary vascular remodeling during chronic hypoxia in neonatal rats.
Biol Neonate. 2006;90(2):135-44. doi: 10.1159/000092518. Epub 2006 Mar 19.
7
Pharmacological management of renal fibrotic disease.
Expert Opin Pharmacother. 2006 Mar;7(4):377-86. doi: 10.1517/14656566.7.4.377.
8
Coronary-artery stents.
N Engl J Med. 2006 Feb 2;354(5):483-95. doi: 10.1056/NEJMra051091.
9
Mitochondrial aldehyde dehydrogenase-2 (ALDH2) Glu504Lys polymorphism contributes to the variation in efficacy of sublingual nitroglycerin.
J Clin Invest. 2006 Feb;116(2):506-11. doi: 10.1172/JCI26564. Epub 2006 Jan 26.
10
Antifibrotic agents for liver disease.
Am J Transplant. 2006 Jan;6(1):12-9. doi: 10.1111/j.1600-6143.2005.01143.x.
Zotero 插件